Gilead Sciences (GILD) EBT Margin (2009 - 2026)
Gilead Sciences' (GILD) quarterly EBT Margin came in at 131.41% in Q2 2026, down 16571.0% on a YoY basis from N/an in Q2 2025, and down 454.5% quarter-over-quarter from 37.07% in Q1 2026.
Powered by 
Analysis
Gilead Sciences (GILD) EBT Margin (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported EBT Margin for 18 consecutive years, with 131.41% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin fell 16571.0% year-over-year to 131.41%; the trailing twelve-month figure through Jun 2026 stood at 6.42% (down 3137.0% YoY), and the FY2025 full-year result was 33.27%, up 3087.0% from the prior year.
- EBT Margin retreated to 131.41% in Q2 2026 per GILD's latest filing, from 37.07% in the prior quarter.
- Across five years, EBT Margin topped out at 46.87% in Q3 2025 and bottomed at 131.41% in Q2 2026.
- Historically, EBT Margin has averaged 12.55% across 5 years, with a median of 25.48% in 2025.
- The sharpest annual moves came in 2025 and 2026: EBT Margin soared 9183 bps in 2025, then slumped 16571 bps in 2026.
- Over 5 years, EBT Margin stood at 27.49% in 2022, then dropped by 15 bps to 23.24% in 2023, then grew by 23 bps to 28.63% in 2024, then fell by 8 bps to 26.22% in 2025, then slumped by 601 bps to 131.41% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 131.41%, 37.07%, and 26.22% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -20,427.46% |
| 10 | Insmed | 27.99 Bn | 26.83 Bn | 358.27 Mn | -2.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -131.41% |
| Mar 31, 2026 | 37.07% |
| Dec 31, 2025 | 26.22% |
| Sep 30, 2025 | 46.87% |
| Jun 30, 2025 | 34.30% |
| Mar 31, 2025 | 24.73% |
| Dec 31, 2024 | 28.63% |
| Sep 30, 2024 | 12.67% |
| Jun 30, 2024 | 29.52% |
| Mar 31, 2024 | -67.10% |
| Dec 31, 2023 | 23.24% |
| Sep 30, 2023 | 32.87% |
| Jun 30, 2023 | 24.06% |
| Mar 31, 2023 | 20.47% |
| Dec 31, 2022 | 27.49% |
| Sep 30, 2022 | 34.54% |
| Jun 30, 2022 | 24.01% |
| Mar 31, 2022 | -2.31% |
| Dec 31, 2021 | 10.48% |
| Sep 30, 2021 | 46.33% |